AlphaCrest Capital Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-42,944
Closed -$3.55M 387
2022
Q3
$3.55M Buy
42,944
+39,367
+1,101% +$3.79M 0.22% 67
2022
Q2
$340K Sell
3,577
-2,341
-40% -$242K 0.02% 1077
2022
Q1
$697K Sell
5,918
-932
-14% -$105K 0.04% 732
2021
Q4
$887K Sell
6,850
-14,861
-68% -$1.73M 0.03% 848
2021
Q3
$2.46M Buy
21,711
+12,415
+134% +$1.42M 0.13% 209
2021
Q2
$963K Sell
9,296
-42,148
-82% -$3.97M 0.04% 679
2021
Q1
$4.3M Buy
51,444
+34,031
+195% +$2.88M 0.24% 85
2020
Q4
$1.59M Buy
17,413
+3,015
+21% +$250K 0.13% 189
2020
Q3
$1.15M Sell
14,398
-25,195
-64% -$1.97M 0.12% 210
2020
Q2
$2.74M Buy
39,593
+12,935
+49% +$919K 0.46% 21
2020
Q1
$1.68M Buy
26,658
+537
+2% +$38.7K 0.2% 116
2019
Q4
$2.03M Buy
26,121
+13,521
+107% +$1.06M 0.17% 110
2019
Q3
$924K Sell
12,600
-22,758
-64% -$1.6M 0.06% 615
2019
Q2
$2.18M Buy
35,358
+29,355
+489% +$1.78M 0.19% 132
2019
Q1
$383K Sell
6,003
-6,297
-51% -$359K 0.06% 570
2018
Q4
$628K Buy
+12,300
New +$622K 0.19% 168

Other funds holding EW

AlphaCrest Capital Management's EW Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Edwards Lifesciences (EW) in Q4 2022, closing a stake of 42,944 shares — an estimated $3.55M sold.

AlphaCrest Capital Management first reported a position in EW in Q4 2018 and held it in 16 quarters. The position peaked at $4.3M in Q1 2021. 1,228 funds tracked by Wall St. Rank hold EW as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Edwards Lifesciences position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 42,944 Edwards Lifesciences shares in Q4 2022, an estimated $3.55M.
  • AlphaCrest Capital Management first reported a position in Edwards Lifesciences in Q4 2018 and held it in 16 quarters.
  • AlphaCrest Capital Management's Edwards Lifesciences position peaked at $4.3M in Q1 2021.
  • 1,228 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.